Zheng Zhao

发表

Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.

P. Bourne, Qingsong Liu, S. Bliven, 2017, Journal of medicinal chemistry.

Molecular mechanisms involved in the side effects of fatty acid amide hydrolase inhibitors: a structural phenomics approach to proteome-wide cellular off-target deconvolution and disease association

Jiadong Ji, Lei Xie, Zheng Zhao, 2016, npj Systems Biology and Applications.

Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

S. Knapp, N. Gray, Qingsong Liu, 2014, ACS chemical biology.

Overview of Current Type I/II Kinase Inhibitors

P. Bourne, Zheng Zhao, 2018, Next Generation Kinase Inhibitors.

Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach.

Zheng Zhao, Li Xie, Lei Xie, 2016, Journal of medicinal chemistry.

Revealing acquired resistance mechanisms of kinase-targeted drugs using an on-the-fly, function-site interaction fingerprint approach

P. Bourne, Zheng Zhao, 2019, bioRxiv.

Crystal Structure of the GRAS Domain of SCARECROW-LIKE7 in Oryza sativa

Qingsong Liu, Yunkun Wu, Zheng Zhao, 2016, Plant Cell.

Progress with covalent small-molecule kinase inhibitors.

Philip E Bourne, Zheng Zhao, P. Bourne, 2018, Drug discovery today.

Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome

Lei Xie, P. Bourne, Zheng Zhao, 2016, bioRxiv.

Structural Insights into Characterizing Binding Sites in Epidermal Growth Factor Receptor Kinase Mutants.

Lei Xie, Philip E Bourne, Zheng Zhao, 2018, Journal of chemical information and modeling.

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase

N. Gray, Qingsong Liu, Xianming Deng, 2015, PloS one.

Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2017, Journal of medicinal chemistry.

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

N. Gray, Qingsong Liu, D. McMillin, 2014, ACS chemical biology.

Developing irreversible inhibitors of the protein kinase cysteinome.

Nathanael S Gray, Qingsong Liu, Zheng Zhao, 2013, Chemistry & biology.

Advance in Reversible Covalent Kinase Inhibitors

P. Bourne, Zheng Zhao, 2021, 2106.11698.

Using the Structural Kinome to Systematize Kinase Drug Discovery

P. Bourne, Zheng Zhao, 2021, Biochemistry.

Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2016, Journal of medicinal chemistry.

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor

Sam W. Lee, N. Gray, Qingsong Liu, 2013, ACS chemical biology.

Discovery of a Potent and Selective DDR 1 Receptor Tyrosine Kinase Inhibitor

Sam W. Lee, N. Gray, Qingsong Liu, 2013 .

Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.

Qingsong Liu, Zheng Zhao, Hong Wu, 2015, Journal of medicinal chemistry.

Advance in Reversible Covalent Kinase Inhibitors

P. Bourne, Zheng Zhao, 2021, 2106.11698.

Revealing acquired resistance mechanisms of kinase-targeted drugs using an on-the-fly, function-site interaction fingerprint approach.

P. Bourne, Zheng Zhao, 2020, Journal of chemical theory and computation.

Brain Penetrant LRRK2 Inhibitor.

Xianming Deng, Nathanael S Gray, Dario R Alessi, 2012, ACS medicinal chemistry letters.

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

A. Look, N. Gray, Qingsong Liu, 2013, ACS chemical biology.

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

N. Gray, Qingsong Liu, Jinhua Wang, 2016, OncoTarget.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies

Qingsong Liu, J. Griffin, S. Fernandes, 2016, Oncotarget.

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances

Qingsong Liu, J. Griffin, S. Fernandes, 2016, OncoTarget.

Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics*

P. Sorger, D. Sabatini, A. Look, 2012, The Journal of Biological Chemistry.

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML

J. Griffin, E. Weisberg, Zheng Zhao, 2016, Oncotarget.

Discovery of a Highly Selective STK16 Kinase Inhibitor.

N. Gray, Qingsong Liu, Jinhua Wang, 2016, ACS chemical biology.

Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs).

Qingsong Liu, Yuexiang Wang, Zhenquan Hu, 2016, Journal of medicinal chemistry.

An easy-to-synthesize multi-photoresponse smart sensor for rapidly detecting Zn2+ and quantifying Fe3+ based on the enol/keto binding mode

H. Shang, Zheng Zhao, Fei Liu, 2019, New Journal of Chemistry.

Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology

Philip E. Bourne, Zheng Zhao, Lei Xie, 2016, BMC Bioinformatics.

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors

N. Gray, Qingsong Liu, W. Hur, 2012, Leukemia.

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

N. Gray, Qingsong Liu, W. Hur, 2013, ACS chemical biology.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.